Chafic Karam, MD
Neurology
Accepting new patients
Sees patients age 18 and up
Penn Neuroscience Center - Neurology
Make an appointmentCall 800-789-7366
Penn Medicine Provider

About me

  • Chief, Neuromuscular Division
  • Professor of Clinical Neurology

Education and training

  • Medical School: Saint Joseph's University Medical School
  • Residency: Hotel Dieu de France
  • Residency: Mount Sinai Beth Israel
  • Residency: Massachusetts General Hospital/Brigham and Women’s Hospital
  • Residency: Mayo Clinic

What my patients think about me

Average Rating

186 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

September 2025
have already recommended them
September 2025
great dr
September 2025
i would highly recommend dr. karam.
September 2025
still getting to know each other, good conversation about options but also staying the course.

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Karam is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Karam C. Clinical Utility of Serum Neurofilament Light Chain in Peripheral Neuropathy. , Muscle Nerve. : 2025

Singh A, Wyatt J, Théaudin M, Karam C, Kasper D, Streubel B, Frascello K, Bondue A. Effectiveness and Utility of Genetic Testing in Establishing a Diagnosis of Hereditary Transthyretin Amyloidosis , Journal of Clinical Medicine.: 2025

Khandelwal N, Sanchirico M, Ajibade A, Munshi K, Vu M, Engel-Nitz N, Steiger C, Anderson AJ, Karam C. Characteristics, Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients with Multifocal Motor Neuropathy: A US Claims Database Cohort Study , J Health Econ Outcomes Res. 2025 Jun 26;12(1):261-268. : 2025

Hsu RT, Wilson J, Karam C. Amyloid Spikes on Optical Coherence Tomography Demonstrating Ocular Involvement in ATTRv Amyloidosis , Neurology. : 2025

Bril V, Drużdż A, Grosskreutz J, Habib AA, Kaminski HJ, Mantegazza R, Sacconi S, Utsugisawa K, Vu T, Boehnlein M, Gayfieva M, Greve B, Woltering F, Vissing J; MG0004 study investigators. Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study. , J Neurol.: 2025

Morganroth J, Karam C. Anti-Myelin-Associated Glycoprotein Neuropathy: Recent Developments , Neurol Clin Pract. : 2025

Rebello, S., Hsu, K., Nativi-Nicolau, J., Karam, C., Grogan, M., Lousada, I., & Maurer, M. S. Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium’s treatment affordability patient and caregiver survey. , Amyloid, 1–10: 2025

Karam C, Pasnoor M, Barohn RJ, Dimachkie MM. Acquired and Genetic Amyloid Neuropathies , Neurol Clin. 2025 Nov;43(4):837-849. : 2025

Qarni TN, Jones FJS, Drachman B, Khella S, Pieretti J, Bustamante NS, Karam C. Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study , Orphanet J Rare Dis.: 2024

Karam C. Navigating the switch from IVIG to FcRn inhibition in CIDP: Clinical insights. J Neurol Sci. 2024 Dec 16;468:123354 , J Neurol Sci., 468(123354): 2024

View all publications